CBI member, AstraZeneca, has announced that it has entered into a global development and commercialisation agreement with Japanese drugs manufacturer Daiichi Sankyo, for the promotion of Daiichi Sankyo’s DS-1062, an antibody drug currently undergoing clinical trials to test for efficacy in the treatment of small-cell lung cancer and triple negative breast cancer.
AstraZeneca and Daiichi Sankyo will jointly develop and commercialize DS-1062 worldwide, except in Japan, where Daiichi Sankyo will maintain exclusive rights. This agreement represents the second global antibody drug conjugate collaboration between the two companies, following a similar agreement in March 2019 between AstraZeneca and Daiichi Sankyo for the Japanese manufacturer’s ENHERTU drug, which is aimed at addressing multiple tumours with one treatment plan.
Pascal Soriot, CEO, AstraZeneca said: “[AstraZeneca] see significant potential in this antibody drug conjugate in lung as well as in breast and other cancers that commonly express TROP2 (a protein that forms on the surface of cancer cells) […] We are delighted to enter this new collaboration with Daiichi Sankyo and to build on the successful launch of ENHERTU to further expand our pipeline and leadership in oncology. We now have six potential blockbusters in oncology with more to come in our early and late pipelines.”
AstraZeneca and Daiichi Sankyo will share equally development and commercialisation costs as well as profits from DS-1062 worldwide, except for Japan. Daiichi Sankyo is expected to book sales in U.S. and certain countries in Europe, while AstraZeneca is expected to book sales in other markets worldwide, including China, Australia, Canada and Russia.
Comments